Pottegård A, Lund LC, Henriksen DP, et al. - Since the use of dipeptidyl peptidase 4 inhibitors (DPP4I) has, on the basis of spontaneous adverse event reports, recently been suspected of causing splanchnic vein thrombosis, researchers reported on a population‐based new user active comparator cohort study addressing this theory, comparing DPP4I initiators (n = 75,042) to initiators of glucagon‐like‐peptide‐1 receptor agonists (GLP1‐RA) or sodium–glucose cotransporter‐2 inhibitors (SGLT2I) (n = 38,718). No evidence of increased risks of splanchnic vein thrombosis has been found across supplementary analyses including lack of any dose‐response patterns. As such, there was no association between DPP4I and splanchnic vein thrombosis risk.